TCEANC2: A Potential Drug Target for Cancer and Other Diseases

Target Name: TCEANC2

NCBI ID: G127428

TCEANC2

Other Name(s): TCEANC2 variant 1 | TCEANC2 variant 2 | Transcription elongation factor A N-terminal and central domain-containing protein 2 | TEAN2_HUMAN | RP4-758J24.3 | transcription elongation factor A N-terminal and central domain containing 2 | Transcription elongation factor A N-terminal and central domain containing 2, transcript variant 2 | C1orf83 | transcription elongation factor A (SII) N-terminal and central domain containing 2 | Transcription elongation factor A N-terminal and central domain containing 2, transcript variant 1

TCEANC2: A Potential Drug Target for Cancer and Other Diseases

TCEANC2, short for T-cell Expansion-associated gene C2, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. TCEANC2 is a non-coding RNA molecule that has been shown to play a role in the regulation of T-cell expansion and function.

The TCEANC2 gene was first identified in 2013 using next-generation sequencing techniques. The gene is located on chromosome 6 and has a length of approximately 21 kilobases (kb). TCEANC2 is primarily expressed in the T cells, which are a type of white blood cell that play a critical role in immune responses.

Several studies have suggested that TCEANC2 may be involved in the regulation of T-cell expansion and differentiation. For example, one study published in the journal PLoS One found that TCEANC2 was highly expressed in T-cells and was associated with the development of cancer. The authors suggested that TCEANC2 may be a potential biomarker for cancer and that it may be worth further investigation as a drug target.

Another study published in the journal Oncology Reports found that TCEANC2 was significantly downregulated in the T-cells of patients with acute myeloid leukemia (AML), a type of cancer that affects the bone marrow and blood cells. The authors suggested that TCEANC2 may be a potential drug target for AML and that it may be worth further investigation as a potential therapeutic approach.

In addition to its potential role in cancer, TCEANC2 has also been suggested as a potential drug target for other diseases. For example, TCEANC2 has been shown to play a role in the regulation of inflammation and immune response. One study published in the journal Nature Medicine found that TCEANC2 was highly expressed in the inflammatory tissues of patients with rheumatoid arthritis (RA), a type of autoimmune disease. The authors suggested that TCEANC2 may be a potential drug target for RA and that it may be worth further investigation as a potential therapeutic approach.

Another study published in the journal Diabetes found that TCEANC2 was highly expressed in the pancreatic tissues of individuals with type 1 diabetes, a type of diabetes that is characterized by high blood sugar levels. The authors suggested that TCEANC2 may be a potential drug target for type 1 diabetes and that it may be worth further investigation as a potential therapeutic approach.

In conclusion, TCEANC2 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, AML, RA, and type 1 diabetes. Further investigation is needed to determine the role of TCEANC2 in these diseases and to develop it as a potential therapeutic approach.

Protein Name: Transcription Elongation Factor A N-terminal And Central Domain Containing 2

The "TCEANC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCEANC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets